Wakita, MitsuruIdei, MayumiSaito, KaoriHoriuchi, YukiYamatani, KotokoIshikawa, SuzukaYamamoto, TakamasaIgawa, GeneHinata, MasanobuKadota, KatsuhikoKurosawa, TaroTakahashi, ShoSaito, TakumiMisawa, ShigekiAkazawa, ChihiroNaito, ToshioMilda, TakashiTakahashi, KazuhisaAi, TomohikoTabe, Yoko2021-04-162021-04-162021Wakita, M., Idei, M., Saito, K., Horiuchi, Y., Yamatani, K., Ishikawa, S., ... & Tabe, Y. (2021). Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests. Plos one, 16(2), e0246536. https://doi.org/10.1371/journal.pone.0246536https://hdl.handle.net/1805/25664We examined the usefulness of five COVID-19 antibody detection tests using 114 serum samples at various time points from 34 Japanese COVID-19 patients. We examined Elecsys Anti-SARS-CoV-2 from Roche, and four immunochromatography tests from Hangzhou Laihe Biotech, Artron Laboratories, Chil, and Nadal. In the first week after onset, Elecsys had 40% positivity in Group S (severe cases) but was negative in Group M (mild-moderate cases). The immunochromatography kits showed 40–60% and 0–8% positivity in Groups S and M, respectively. In the second week, Elecsys showed 75% and 50% positivity, and the immunochromatography tests showed 5–80% and 50–75% positivity in Groups S and M, respectively. After the third week, Elecsys showed 100% positivity in both groups. The immunochromatography kits showed 100% positivity in Group S. In Group M, positivity decreased to 50% for Chil and 75–89% for Artron and Lyher. Elecsys and immunochromatography kits had 91–100% specificity. Elecsys had comparable chronological change of cut-off index values in the two groups from the second week to the sixth week. The current SARS-CoV-2 antibody detection tests do not provide meaningful interpretation of severity and infection status. Its use might be limited to short-term epidemiological studies.enAttribution 4.0 InternationalCOVID-19SARS-CoV-2antibody detection testsArticle